Literature DB >> 21516472

Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Ying-Li Lin1, Xiao-Qiang Liu, Wen-Ping Li, Guang Sun, Chun-Ting Zhang.   

Abstract

OBJECTIVES: H-cadherin, functions as a tumor suppressor, is frequently silenced by promoter methylation in human cancers. The aim of this study was to evaluate the feasibility of using H-cadherin methylation in tumor tissues as a potential biomarker in patients with bladder transitional cell carcinoma (TCC).
MATERIALS AND METHODS: We examined the methylation status of H-cadherin in 133 primary bladder TCC samples and 43 normal bladder epithelial tissues using methylation-specific polymerase chain reaction (MSP) and then analyzed the associations between H-cadherin methylation and clinicopathologic features as well as patients' outcome.
RESULTS: H-cadherin methylation was detected in 47 (35.3%) bladder TCC samples, but not found in controls (P = 0.0000). Moreover, H-cadherin methylation was significantly associated with advanced stage (P = 0.0006), high grade (P = 0.0165), larger tumor size (P = 0.0225), tumor recurrence (P = 0.0106), and poor prognosis (P = 0.0000). In addition, multivariate analysis indicated that H-cadherin methylation is independently associated with poor outcome and had a relative risk of death of 3.832 (P = 0.0071, 95% confidence interval: 1.443-10.176).
CONCLUSIONS: The results suggest that H-cadherin methylation may be used as a potential biomarker for the malignancy of bladder TCC and as an independent prognostic biomarker in patients with bladder TCC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21516472     DOI: 10.1007/s11255-011-9961-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  33 in total

Review 1.  Defining optimal therapy for muscle invasive bladder cancer.

Authors:  Harry W Herr; Zohar Dotan; S Machele Donat; Dean F Bajorin
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

2.  Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.

Authors:  R Maruyama; S Toyooka; K O Toyooka; K Harada; A K Virmani; S Zöchbauer-Müller; A J Farinas; F Vakar-Lopez; J D Minna; A Sagalowsky; B Czerniak; A F Gazdar
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 3.  Bladder cancer: clinical and pathological profile.

Authors:  Antonio Lopez-Beltran
Journal:  Scand J Urol Nephrol Suppl       Date:  2008-09

4.  A novel set of DNA methylation markers in urine sediments for sensitive/specific detection of bladder cancer.

Authors:  Jian Yu; Tongyu Zhu; Zhirou Wang; Hongyu Zhang; Ziliang Qian; Huili Xu; Baomei Gao; Wei Wang; Lianping Gu; Jun Meng; Jina Wang; Xu Feng; Yixue Li; Xuebiao Yao; Jingde Zhu
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

5.  DNA methylation markers and early recurrence in stage I lung cancer.

Authors:  Malcolm V Brock; Craig M Hooker; Emi Ota-Machida; Yu Han; Mingzhou Guo; Stephen Ames; Sabine Glöckner; Steven Piantadosi; Edward Gabrielson; Genevieve Pridham; Kristen Pelosky; Steven A Belinsky; Stephen C Yang; Stephen B Baylin; James G Herman
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

6.  CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients.

Authors:  Andreas Widschwendter; Lennart Ivarsson; Anya Blassnig; Hannes M Müller; Heidi Fiegl; Annemarie Wiedemair; Elisabeth Müller-Holzner; Georg Goebel; Christian Marth; Martin Widschwendter
Journal:  Int J Cancer       Date:  2004-03-20       Impact factor: 7.396

Review 7.  Epigenetic markers as promising prognosticators for bladder cancer.

Authors:  Young Kyoon Kim; Wun-Jae Kim
Journal:  Int J Urol       Date:  2008-08-20       Impact factor: 3.369

8.  A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis.

Authors:  Morgan Rouprêt; Vincent Hupertan; David R Yates; Eva Comperat; James W F Catto; Mark Meuth; Amine Lackmichi; Sylvie Ricci; Roger Lacave; Bernard Gattegno; François Richard; Freddie C Hamdy; Olivier Cussenot
Journal:  BJU Int       Date:  2008-03-04       Impact factor: 5.588

Review 9.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

10.  The present and future burden of urinary bladder cancer in the world.

Authors:  Martine Ploeg; Katja K H Aben; Lambertus A Kiemeney
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

View more
  6 in total

Review 1.  DNA methylation-based biomarkers in bladder cancer.

Authors:  Raju Kandimalla; Angela A van Tilborg; Ellen C Zwarthoff
Journal:  Nat Rev Urol       Date:  2013-04-30       Impact factor: 14.432

2.  Aberrant methylation of CDH11 predicts a poor outcome for patients with bladder cancer.

Authors:  Ying-Li Lin; Shi-Liang Gui; Jian-Guo Ma
Journal:  Oncol Lett       Date:  2015-06-08       Impact factor: 2.967

Review 3.  Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?

Authors:  Yong-June Kim; Wun-Jae Kim
Journal:  Investig Clin Urol       Date:  2016-05-25

4.  Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.

Authors:  Ekaterina Olkhov-Mitsel; Andrea J Savio; Ken J Kron; Vaijayanti V Pethe; Thomas Hermanns; Neil E Fleshner; Bas W van Rhijn; Theodorus H van der Kwast; Alexandre R Zlotta; Bharati Bapat
Journal:  Transl Oncol       Date:  2017-02-03       Impact factor: 4.243

5.  Aberrant methylation of CDH13 is a potential biomarker for predicting the recurrence and progression of non muscle invasive bladder cancer.

Authors:  Ying-Li Lin; Pei-Gen Xie; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2014-09-04

6.  Clinical significance of CDH13 promoter methylation as a biomarker for bladder cancer: a meta-analysis.

Authors:  Feng Chen; Tao Huang; Yu Ren; Junjun Wei; Zhongguan Lou; Xue Wang; Xiaoxiao Fan; Yirun Chen; Guobin Weng; Xuping Yao
Journal:  BMC Urol       Date:  2016-08-30       Impact factor: 2.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.